首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage.
【24h】

Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage.

机译:急性普伐他汀治疗对动脉瘤性蛛网膜下腔出血患者的抢救治疗强度,住院时间和6个月结局的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: We have previously demonstrated that acute pravastatin therapy after aneurysmal subarachnoid hemorrhage ameliorates vasospasm-related delayed ischemic deficits. This study assesses the effects of pravastatin on the frequency and intensity for rescue therapy, length of inpatient stay, and long-term outcome at 6 months. METHODS: Eighty aneurysmal subarachnoid hemorrhage patients (age 18 to 84 years, onset 1.8+/-1.3 days) were randomized to receive daily oral pravastatin (40 mg) or placebo for up to 14 days. Clinical events were recorded during the trial. Six-month outcome was assessed using the Short Form 36 and the modified Rankin Scale. RESULTS: Although no significant difference in the outcome at discharge was found between the trial groups, multivariate analysis showed pravastatin therapy reduced unfavorable outcome by 73% (P=0.041). The benefit persisted at 6 months (P=0.063) and was notable in the physical (P<0.001) and psychosocial (P<0.001) aspects measured using Short Form 36. Furthermore, the acute pravastatin therapy reduced the requirement for triple-H therapy (hypertensive, hypervolemic, hemodilution; P=0.045) and mortality related to vasospasm (P=0.02) and sepsis (P=0.001); no significant difference was found in the length of inpatient stay between the trial groups. CONCLUSIONS: This trial demonstrates that acute statin treatment reduces traditional rescue therapy for vasospasm after aneurysmal subarachnoid hemorrhage. Improvement in early outcome has proved robust at 6 months, particularly in relation to physical and psychosocial (Short Form 36) outcome.
机译:背景与目的:我们先前已经证明,动脉瘤性蛛网膜下腔出血后的急性普伐他汀治疗可改善血管痉挛相关的延迟性缺血性缺陷。这项研究评估了普伐他汀对抢救治疗的频率和强度,住院时间和6个月的长期结局的影响。方法:将80例动脉瘤性蛛网膜下腔出血患者(年龄18至84岁,发病时间1.8 +/- 1.3天)随机接受每日口服普伐他汀(40毫克)或安慰剂治疗,最多14天。试验期间记录了临床事件。使用简短表格36和改良的Rankin量表评估六个月的结局。结果:尽管试验组之间出院结局无明显差异,但多因素分析显示普伐他汀治疗可将不良结局降低73%(P = 0.041)。受益持续了6个月(P = 0.063),在短期(Short Form 36)测量中在身体方面(P <0.001)和社会心理方面(P <0.001)显着。此外,急性普伐他汀疗法减少了三H疗法的需要(高血压,高血容量,血液稀释; P = 0.045)和与血管痉挛有关的死亡率(P = 0.02)和败血症(P = 0.001);试验组之间的住院时间没有显着差异。结论:该试验证明急性他汀类药物治疗减少了动脉瘤性蛛网膜下腔出血后血管痉挛的传统抢救疗法。事实证明,在6个月时,早期结果的改善是有力的,特别是在身体和心理方面(简短表格36)方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号